Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $7.50 Consensus PT from Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $7.50.

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Wednesday, October 8th. Morgan Stanley assumed coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price for the company. Finally, Wedbush began coverage on Sana Biotechnology in a research note on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price for the company.

Institutional Trading of Sana Biotechnology

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its position in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after acquiring an additional 9,501 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Sana Biotechnology in the third quarter valued at $39,000. Griffin Asset Management Inc. bought a new stake in Sana Biotechnology in the third quarter valued at $41,000. Hoey Investments Inc. bought a new stake in Sana Biotechnology in the second quarter valued at $33,000. Finally, BNP Paribas Financial Markets grew its position in Sana Biotechnology by 46.9% in the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after acquiring an additional 4,931 shares during the period. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Trading Down 6.1%

Shares of NASDAQ SANA opened at $5.25 on Friday. The business has a fifty day simple moving average of $3.83 and a 200 day simple moving average of $3.17. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -4.95 and a beta of 1.91. Sana Biotechnology has a one year low of $1.26 and a one year high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, research analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.